Table 2.
Clinical characteristics and past treatments of 14 patients enrolled.
| Patient | Age/sex | Anatomical pattern | Laterality | Systemic disease | Preceding biologics and their dose |
|---|---|---|---|---|---|
| 1 | 42/M | Nodular AS | Bilateral | GPA | — |
| 2 | 76/M | Necrotizing AS | Unilateral | MPA | — |
| 3 | 66/M | Diffuse AS | Unilateral | RA | — |
| 4 | 16/F | Posterior scleritis | Unilateral | Idiopathic | — |
| 5 | 32/F | Diffuse AS | Unilateral | GPA | — |
| 6 | 56/F | Diffuse AS | Bilateral | RA | ADA (40 mg/2 weeks), ABA (125 mg/week), IFX (5 mg/kg/4 weeks) |
| 7 | 46/M | Diffuse AS | Unilateral | PsA | ADA 40 mg/2 weeks, IFX (5 mg/kg/4 weeks) |
| 8 | 18/F | Posterior scleritis | Unilateral | Idiopathic | RTX (2 gr/6 months) |
| 9 | 59/M | Nodular AS | Bilateral | RA | — |
| 10 | 66/M | Posterior scleritis | Unilateral | FMF | — |
| 11 | 54/F | Diffuse AS | Bilateral | RA | ADA (40 mg/2 weeks) |
| 12 | 52/F | Diffuse AS | Unilateral | RA | — |
| 13 | 34/F | Diffuse AS | Unilateral | RA | — |
| 14 | 45/F | Diffuse AS | Bilateral | RA | ETN (50 mg/week), ADA (40 mg/2 weeks), TCZ (162 mg/week), RTX (2 gr/6 months) |
ABA: abatacept; ADA: adalimumab; AS: anterior scleritis; F: female; GPA: granulomatosis with polyangiitis; IFX: infliximab; M: male; MPA: microscopic polyangiitis; PsA: psoriatic arthritis; RA: rheumatoid arthritis; RTX: rituximab; TCZ: tocilizumab.